Comparing Revenue Performance: Alnylam Pharmaceuticals, Inc. or Teva Pharmaceutical Industries Limited?

Alnylam vs. Teva: A Decade of Revenue Shifts

__timestampAlnylam Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20145056100020272000000
Thursday, January 1, 20154109700019652000000
Friday, January 1, 20164715900021903000000
Sunday, January 1, 20178991200022385000000
Monday, January 1, 20187490800018854000000
Tuesday, January 1, 201921975000016887000000
Wednesday, January 1, 202049285300016658000000
Friday, January 1, 202184428700015878000000
Saturday, January 1, 2022103741800014925000000
Sunday, January 1, 2023182829200015846000000
Monday, January 1, 2024224824300016544000000
Loading chart...

Unleashing the power of data

A Tale of Two Pharmaceutical Giants: Alnylam vs. Teva

In the ever-evolving pharmaceutical industry, revenue performance is a key indicator of a company's market position and growth potential. Alnylam Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited, two prominent players, have shown contrasting revenue trajectories from 2014 to 2023. Alnylam, a leader in RNA interference therapeutics, has seen its revenue skyrocket by over 3,500% during this period, reflecting its innovative breakthroughs and expanding market reach. In contrast, Teva, a global leader in generic drugs, experienced a 22% decline in revenue, highlighting challenges in the generic drug market and increased competition. This comparison underscores the dynamic nature of the pharmaceutical sector, where innovation and adaptability are crucial for sustained growth. As we look to the future, the strategic decisions made by these companies will be pivotal in shaping their financial landscapes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025